Lymphoma & Leukemia Program
About Lymphoma and Leukemia
Since lymphoma is a cancer of the immune system, a major scientific goal of the Lymphoma and Leukemia Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
Program Aims:
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Program Directors
Program Directory
Lymphoma and Leukemia Clinical Trials
-
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Stanford is currently accepting patients for this trial. -
JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation
Stanford is currently accepting patients for this trial. -
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford is currently accepting patients for this trial. -
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Stanford is currently accepting patients for this trial.